Clinical Research Directory
Browse clinical research sites, groups, and studies.
Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer
Sponsor: Sahlgrenska University Hospital
Summary
The goal of this prospective observational study is to learn about the short- and long-term effects of treating men over the age of 18 with good prognosis metastatic testicular cancer with either primary retropertioneal lymph node dissection, RPLND, (for low-stage metastastic seminoma) or three doses of chemotherapy for metastastic seminoma or nonseminoma. The main question it aims to answer is: Does primary RPLND lower the risk of side-effects compared to receiving chemotherapy?
Official title: Testicular Cancer Treatment: Assessing Quality of Life in Good Prognosis Metastastic Disease
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2026-03-19
Completion Date
2032-03-25
Last Updated
2026-03-27
Healthy Volunteers
No
Interventions
primary RPLND for low-stage metasatatic seminoma
surgical lymph node dissection
3 courses of chemotherapy; Blemocin, Etoposide and Platinum (BEP)
systemic tretament for good prognosis metastastic testicular cancer
Locations (1)
Sahlgrenska University Hospital
Gothenburg, Göteborg, Sweden